Early Detection and Cancer Interception

Early Detection and Cancer Interception are at the heart of SU2C’s mission to transform the way cancer is diagnosed and treated. This pioneering initiative focuses on identifying and addressing cancer at its earliest stages—before it fully develops. By shifting the focus from treatment to early intervention, SU2C aims to improve survival rates and provide patients with better outcomes.

Strategies and Impact

SU2C’s Early Detection and Cancer Interception initiatives focus on proactive approaches that identify cancer risks and intervene early. This strategy includes:

  • Advanced Screening Techniques: Utilizing cutting-edge technologies such as liquid biopsies, imaging, and molecular analysis to detect cancer markers before clinical symptoms arise.
  • Prevention and Early Intervention: Research into how cancer begins and evolves has paved the way for treatments that can be applied at the earliest stages of cancer formation, aiming to halt progression before the disease becomes aggressive.

These methods reflect a shift from the conventional reactive approach to one that emphasizes prevention and early management, offering patients more options and potentially more effective outcomes.

Cancer Interception: SU2C Teams have explored innovative strategies to detect and treat cancer at the earliest possible stage, potentially even before a cancer cell fully forms.

Advances in Early Detection: Research funded by SU2C has led to groundbreaking methods for detecting cancer earlier, which can dramatically improve the effectiveness of treatment and overall patient survival.

Scientist in a laboratory examining samples through a lens.

AI is revolutionizing early-stage detection. With this technology, we can take our fight from defense to offense, leaving cancer with nowhere to hide.

Using AI, investigators can…

AI can analyze enormous recurrence sets of biodata—more than scientists could analyze manually in several lifetimes. This allows investigators to trace where, when, and how cancer might strike and design precise interventions.

AI can quickly identify the presence of cancer cells in routine scans such as mammograms that might otherwise go undetected by the human eye.

AI can model a patient’s response to treatments such as immunotherapy based on their cancer’s specific genome. This enables doctors to deliver the right drug for each patient the first time.

AI can support digital pathology by identifying the precise boundaries of a tumor to help doctors eliminate as much cancer as possible and minimize damage to healthy tissues.

AI can help monitor each patient’s risk of cancer recurrence and inform survivors’ follow-up plans to help keep them cancer-free for a lifetime.

Early-stage detection can help close health equity gaps, giving all people with cancer the chance to become long-term survivors.

Cancer care advances have not yet reached all Americans equally. From early screenings to better access to specialty care, SU2C is committed to building a more equitable future for people with cancer. Our plan includes increasing diversity in the clinical trials we fund, supporting awareness campaigns, and funding research aimed at improving cancer outcomes and screening rates for medically underserved communities.

  • For most cancers, Black Americans still face the lowest survival rate of any racial or ethnic group.

  • Hispanic Americans are more likely to be diagnosed with advanced stages of disease and experience poor quality of life following a cancer diagnosis.

  • Asian Americans are the only racial or ethnic group in the United States for whom cancer is the leading cause of death in both men and women.

  • Native Americans face reduced healthcare access, leading to higher rates of advanced-stage disease for screening-detectable cancers and, as a result, poorer outcomes for many cancers.l or ethnic group.

Looking Ahead: The Future of Early Detection and Cancer Interception

SU2C remains dedicated to expanding its Early Detection and Cancer Interception efforts, supporting new technologies and research that can identify cancer risks sooner and prevent the progression of the disease. By continuing to fund and advocate for these proactive strategies, SU2C seeks to make early detection a standard part of cancer care.

“Stand Up To Cancer’s investment in my research goes beyond supporting me as an early-stage investigator—it reflects their commitment to cancer health equity and the recognition that eliminating cancer disparities requires addressing social, environmental, and political factors that shape our biology. From genes to society, bench to community, Stand Up To Cancer’s dedication to cancer health equity is truly standing up for the future of cancer care.“

Katherine Y. Tossas, Ph.D., Early Career Investigator, SU2C Lung Cancer Health Equity Research Team

Katherine Y. Tossas, Ph.D., researcher, profile picture.

Katherine Y. Tossas, Ph.D.

  • Impact at a Glance

    Doctor and patient holding placards showcasing their support for groups affected by cancer.
    0+
    INSTITUTIONS
    0+
    RESEARCHERS
    0+
    CLINICAL TRIALS
    0+
    RESEARCH TEAMS
    0+
    CLINICAL TRIAL PATIENTS

  • Case Statement

    Julian Adams, PhD, President and CEO of SU2C, speaking at a conference.

    A future without cancer is in sight. Together, we can
    make it a reality.